Literature DB >> 18211567

Epidemiology and pathophysiology of immune thrombocytopenic purpura.

Terry Gernsheimer1.   

Abstract

Immune thrombocytopenic purpura (ITP) is characterized by the presence of antiplatelet antibodies and immune platelet destruction. The disorder has been described as having a predilection for young women over men. Bone marrow megakaryocytes appear morphologically and quantitatively normal, and early platelet kinetic studies were consistent with reduced platelet survival as the primary abnormality in ITP. During the last 10-20 yr, understanding of the kinetics of this disorder has evolved with evidence that platelet survival is not as abbreviated as previously thought. Thrombopoietin levels are only minimally elevated, if at all, suggesting marrow stimulation and platelet production may not be maximized. Megakaryocyte physiology appears to be altered in ITP, also suggestive of diminished platelet production. It appears both platelet survival and production are impaired in ITP. The epidemiology of ITP is reviewed here and the pathophysiology of ITP is reconsidered.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18211567     DOI: 10.1111/j.1600-0609.2007.00998.x

Source DB:  PubMed          Journal:  Eur J Haematol Suppl        ISSN: 0902-4506


  13 in total

Review 1.  Translational Mini-Review Series on B Cell-Directed Therapies: The pathogenic role of B cells in autoantibody-associated autoimmune diseases--lessons from B cell-depletion therapy.

Authors:  M J Leandro; I de la Torre
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

2.  Privigen immune globulin intravenous (human), 10% liquid.

Authors: 
Journal:  P T       Date:  2011-08

3.  Cerebral infarction in idiopathic thrombocytopenic purpura: a case report.

Authors:  Karim Mahawish; Nicholas Pocock; Sujeeth Mangarai; Anil Sharma
Journal:  BMJ Case Rep       Date:  2009-06-04

4.  Ischemic stroke associated with immune thrombocytopenia.

Authors:  HongMei Zhao; YaJun Lian; HaiFeng Zhang; NanChang Xie; YanLun Gao; ZhongYue Wang; Yi Zhang
Journal:  J Thromb Thrombolysis       Date:  2015-08       Impact factor: 2.300

5.  Immunologic effects of rituximab on the human spleen in immune thrombocytopenia.

Authors:  Sylvain Audia; Maxime Samson; Julien Guy; Nona Janikashvili; Jennifer Fraszczak; Malika Trad; Marion Ciudad; Vanessa Leguy; Sabine Berthier; Tony Petrella; Serge Aho-Glélé; Laurent Martin; Marc Maynadié; Bernard Lorcerie; Patrick Rat; Nicolas Cheynel; Emmanuel Katsanis; Nicolas Larmonier; Bernard Bonnotte
Journal:  Blood       Date:  2011-08-29       Impact factor: 22.113

6.  Efficacy and safety of ClairYg®, a ready-to-use intravenous immunoglobulin, in adult patients with primary immune thrombocytopenia.

Authors:  Borhane Slama; Olivier Fain; Hervé Maisonneuve; Eric Jourdan; Jean-François Viallard; Rabye Ouaja; Ousmane Alfa-Cissé; Bertrand Godeau
Journal:  Am J Blood Res       Date:  2017-01-15

7.  Primary percutaneous coronary intervention for acute myocardial infarction in a young female with idiopathic thrombocytopenic purpura: a case report and review.

Authors:  Ahmet Yildiz; Ugur Coskun; Ozlem Esen Batukan; Kudret Keskin
Journal:  Case Rep Med       Date:  2010-03-24

Review 8.  The thrombocytopenia of WAS: a familial form of ITP?

Authors:  Ted S Strom
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

9.  A novel canine model of immune thrombocytopenia: has immune thrombocytopenia (ITP) gone to the dogs?

Authors:  Dana N LeVine; Adam J Birkenheuer; Marjory B Brooks; Shila K Nordone; Dwight A Bellinger; Sam L Jones; Thomas H Fischer; Stephen E Oglesbee; Kahlina Frey; Nicole S Brinson; Allison P Peters; Henry S Marr; Alison Motsinger-Reif; Sif Gudbrandsdottir; James B Bussel; Nigel S Key
Journal:  Br J Haematol       Date:  2014-07-08       Impact factor: 6.998

Review 10.  Pathobiology of secondary immune thrombocytopenia.

Authors:  Douglas B Cines; Howard Liebman; Roberto Stasi
Journal:  Semin Hematol       Date:  2009-01       Impact factor: 3.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.